A Sept. 20 story,

BroadVision Goes Head-to-Head With B2B Biggies, incorrectly reported that senior analyst Nick Moore of

Jurika and Voyles

in Oakland, Calif., has held a short position in

BroadVision

(BVSN:Nasdaq) shares. In fact, Moore has been long BroadVision in the past. In addition, BroadVision is located in Redwood City, Calif., not Redwood Shores.

(corrected, Sept. 22)

A Sept. 19 story,

International Fibercom Rises, mistakenly reported that an increase in International Fibercom's (IFCI:Nasdaq) share price was related to an announced partnership with Next Level Communications (NXTV:Nasdaq) In fact, the partnership was announced in early August and the reason behind the move was undetermined. (co rrected Sept. 22)

A Sept. 21 story,

Euro's Weakness No Problem for Tech Stocks, misidentified analyst Charlie Glavin's firm. He works at

Credit Suisse First Boston

, not

Lehman Brothers

. (

corrected Sept. 22

)

A Sept. 20 story,

eBay Sets $3 Billion Revenue Goal as Shares Soar 17%, incorrectly identified a closely held Internet company as

OnDelay

. Though the company being referenced owns the domain name ondelay.com, the company's actual name is

Andale

. (

corrected Sept. 22

)

A Sept. 19 story,

International Fibercom Rises, mistakenly reported that an increase in

International Fibercom's

(IFCI:Nasdaq) share price was related to an announced partnership with

Next Level Communications

(NXTV:Nasdaq). In fact, the partnership was announced in early August and the reason behind the move was undetermined. (

corrected Sept. 21

)

A Sept. 20 story,

Adobe Sees Strong Revenue Growth, mistakenly reported that

Adobe.com

attracts 11 million visitors each day. In fact, the Web site attracts that many users each month. (

corrected Sept. 21

)

A Sept. 14 story,

TST Recommends

Immunomedics Shuts Down Drug Trials After Patient Death, mistakenly reported that

Immunomedics

(IMMU:Nasdaq) halted clinical trials of an experimental cancer drug, according to

Legg Mason

analyst Stefan Loren. In fact, Loren said only that a trial of an Immunomedics drug at the

Garden State Cancer Center

was halted -- not that it was halted by Immunomedics. (

corrected Sept. 19

)

A Sept. 18 story,

Cabletron Spinoff Parade Begins With Riverstone Filing, incorrectly reported that

Luminent

had yet to file for its initial public offering. In fact, Luminent filed for its IPO on July 26. (

corrected Sept. 19

)

The Sept. 18 Market Story,

Worlds Collide and Dow Gets Caught in the Middle, misquoted Sam Ginzburg, senior managing director of equity trading at

Gruntal

, as saying, "We have been shorting into any weakness on the Comp," referring to the

Nasdaq Composite Index

. In fact, Ginzburg said, "We have been shorting into any strength on the Comp." (

corrected Sept. 19

)

A Sept. 14 story,

Brokers Keep Rallying, but the Numbers Don't Add Up, mistakenly stated that asset-management revenue made up only 2% of overall revenue at

Morgan Stanley Dean Witter

(MWD:NYSE) in the first half of the firm's fiscal year. In fact, asset-management accounted for 8.5% of net revenue. (

corrected Sept. 19

)

A Sept. 18 story,

Companies Being Beaten Up in Cyberspace?, mistakenly reported that

Titan

(TTN:NYSE) is being sued by shareholders for alleged mismanagement. That isn't the case. (

corrected Sept. 18

)

A Sept. 14 story,

Some Oracle Disciples in Fund World Are Losing Faith, incorrectly reported that the number of growth funds owning

Oracle

(ORCL:Nasdaq) fell to 113 from 222 between March 31 and July 31, and that the number of tech funds owning Oracle shares fell to 15 from 44 over the same period. The number of growth and tech funds owning Oracle was actually 165 and 49, respectively, on July 31. (

corrected Sept. 18

)